US37733W2044 - ADR
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong...
Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.
Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com users have recently been watching Glaxo (GSK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer reports positive data for Abrysvo vaccine, showing high efficacy in preventing respiratory syncytial virus (RSV) in adults 60 years and older.
GSK announces positive results from pivotal trial of oral gonorrhoea drug, gepotidacin.
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.
The company unexpectedly came in with fourth-quarter earnings that beat projections.
Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop.
AnaptysBio (ANAB) stock rises after Piper Sandler initiated coverage with a bullish view, citing a catalyst-rich period for the biotech in 2024/25. Read more here.
Citi upgrades GSK (GSK) to Buy following positive Phase 3 data for its multiple myeloma drug, Blenrep. Read more here.
Shares of Moderna (MRNA) dropped as concerns arise over the long-term efficacy of its experimental vaccine against respiratory syncytial virus (RSV). Read more here.